NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.